New treatment plan for chronic hives not helped by antihistamines
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a treatment plan using remibrutinib (a pill) and omalizumab (a biologic shot) for adults with chronic spontaneous urticaria (chronic hives) that are not well controlled by antihistamines. The goal is to see if this combination can reduce itching and hives better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have had chronic spontaneous urticaria (long-lasting hives without a clear trigger) for at least 2 months.
- You have had itching and hives for at least 6 weeks in a row, despite taking non-drowsy antihistamines (like cetirizine or loratadine).
- Your hives are still not well controlled, with a score of at least 16 on a weekly hives severity scale.
- You have had hives documented in the last 2 months, either by the study team or in your medical history.
- You are willing to fill out a daily hives diary for the whole study.
- You have not taken remibrutinib, other BTK inhibitors, or certain biologics for hives before, and you do not have significant bleeding risk, liver disease, or other major health issues that could make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program offers remibrutinib, an experimental oral medication, to adults with chronic spontaneous urticaria (long-lasting hives without a known trigger) that hasn't improved with standard antihistamines or omalizumab. It aims to see if this drug can reduce symptoms when other options haven't worked.
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
This study follows people with chronic spontaneous urticaria (long-lasting hives with no clear cause) who are starting a new medicine called remibrutinib or dupilumab. It aims to see how well these treatments work in everyday life.
This study observes how remibrutinib (a newer medication) works for chronic hives (CSU) when prescribed in routine clinical practice in Germany. Remibrutinib is used when standard allergy medications don't work well enough. The study tracks your symptoms and treatment over 24 months to understand how well it helps real patients.
This study is testing an experimental daily pill called ritlecitinib for adults whose chronic hives don’t go away with standard antihistamines. It may be a new option if your hives are active and you are not on omalizumab or are willing to stop it for several months.
Hear when a new Chronic Spontaneous Urticaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.